NewsEvents

Your Yourlocation: Home > Treatment of 180 cases of chronic obstructive pulmonary disease with tiotropium bromide(136310-93-5) powder

To observe the effect of tiotropium bromide(136310-93-5) on the maintenance of patients with chronic obstructive pulmonary disease (COPD), improved lung function, improved quality of life and reduced acute exacerbation.

Methods: 360 patients with stable COPD were randomly divided into observation group and control group. Both groups were given anti-inflammatory, cough, expectorant, oxygen and other conventional treatment, if the acute exacerbation, to salbutamol aerosol emergency treatment. The control group was inhaled with ipratropium bromide aerosol inhalation (5 mg, 3 times / day). The observation group was treated with HandiHaler powder (1 tablet / time, 1 time / day). Two groups of patients were treated for 12 weeks for a course of treatment. 

Results: Compared with the control group, the lung function index, 6 min walking distance and dyspnea index were improved in the 6th week, 12 weeks after treatment, and the improvement was more significant in the observation group than in the control group (P <0.05). The incidence of acute exacerbation was significantly lower than that of the control group (P <0.05). In the course of treatment, the adverse reactions were mild in the two groups, and there was no significant difference (P> 0.05).

Conclusion: Tiotropium bromide(136310-93-5) powder for the maintenance of COPD patients can significantly improve lung function, reduce airway obstruction and dyspnea, improve the quality of life, can significantly reduce the risk of acute exacerbation of patients, worthy of clinical promotion.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved